Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Durect Corporation has completed dosing of both the phase I pharmacokinetic study for its Transdur-based sufentanil patch, and the first cohort of the on-going phase II clinical study for its Saber-based post-operative pain relief product.
Subscribe to our email newsletter
The Transdur-based transdermal sufentanil product is intended to provide extended chronic pain relief for up to seven days, as compared to the three days of relief provided with currently available opioid patches such as Janssen Pharmaceutica’s Duragesic.
The Saber-based post-operative pain relief depot product is intended to be administered around a surgical site after surgery to provide up to 72 hours of regional pain relief and is based on the company’s patented Saber delivery system. Durect believes this product could potentially reduce hospital stays and the amount of traditional post-surgical pain medications needed by patients, as well as the side effects that result from the use of concomitant opioid medications.
“The completion of dosing of the first cohort for our on-going phase II trial for our Saber-Bupivacaine product candidate is an important milestone and advances this product to the next step in the clinical program,” said James Brown, Durect’s president and CEO. Durect is now actively enrolling patients in the second cohort.
“We believe that these products, once approved, will provide a significant improvement over currently available pain management therapies on the market today,” he added.